MYC and metastatic malignant neoplasm in the lymph nodes: There was no statistically significant correlation between the clinicopathological factors and c-MYC GCN gain in primary, distant metastatic, and lymph-node metastatic tumors from cohort 2 CRC patients (P > 0.05; data not shown).